Research To Practice | Oncology Videos

Featuring an interview with Dr Charles Powell, including the following topics: Role of the pulmonologist in the cancer care team; frequency of fatal and Grade 4 interstitial lung disease (ILD) with antibody-drug conjugates (0:00) Pathophysiology of pneumonitis associated with checkpoint inhibitors versus antibody-drug conjugates; differences in presentation of ILD based on the cause of disease (8:04) Myths and misperceptions about drug-related pneumonitis among general medical oncologists (14:08) Monitoring for the onset of ILD using remote technology; typical time to onset of ILD (21:45) Risk factors for the development of ILD among patients receiving anticancer therapy (25:58) Incidence of ILD with bispecific antibodies; mechanisms underlying differences in the incidence of ILD associated with various antibody-drug conjugates (33:45) CME information and select publications

Featuring perspectives from Dr Jacob Sands, including the following topics: Introduction: Journal Club (0:00) Case: A woman in her mid 50s with extensive-stage small cell lung cancer (ES-SCLC) who had an excellent response to chemotherapy with immunotherapy (IO) and has been on maintenance IO for 2 years — Adam R Miller, MD (22:05) Case: A woman in her mid 60s with ES-SCLC who presented with superior vena cava syndrome and has a near complete remission with chemo-IO — Namrata I Peswani, MD (28:27) Case: A woman in her late 80s with metastatic SCLC possibly of adrenal origin who has an excellent response to chemo-IO — John Yang, MD (34:14) Case: A woman in her mid 70s with recurrent ES-SCLC who has prolonged disease control on topotecan/trilaciclib — Ferdy Santiago, MD (41:09) Case: A woman in her late 50s with ES-SCLC and brain metastases who responds to chemo-IO but later experiences disease progression (PD) and has toxicity with topotecan — Dr Miller (45:34) Case: A woman in her late 60s with ES-SCLC who has PD on chemo-IO but responds to lurbinectedin with only mild toxicity — Mohamed K Mohamed, MD, PhD (48:28) Case: A man in his early 70s with synchronous Stage III SCLC and Stage I non-small cell lung cancer who receives concurrent chemoradiation therapy — Daniel R Carrizosa, MD, MS (1:00:34) CME information and select publications

Featuring an interview with Dr Mansoor Raza Mirza, including the following topics: Delivery of care models for endometrial cancer (0:00) Molecular profiling and treatment for endometrial cancer (1:57) Current use of immunotherapy for the management of endometrial cancer (8:56) Mitigating and managing immunotherapy-associated adverse events for patients with endometrial cancer (13:40) Immune checkpoint inhibitors for localized endometrial cancer(18:51) Practical considerations in the care of patients with endometrial cancer (22:17) Targeted therapy for patients with endometrial cancer (30:08) CME information and select publications

Featuring a slide presentation and related discussion from Dr Mansoor Raza Mirza, including the following topics: Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00) Immunotherapy for mismatch repair-proficient endometrial cancer (9:18) Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11) CME information and select publications

Featuring perspectives from Dr John Strickler, including the following topics: Introduction (0:00) Case: A man in his early 60s with gastroesophageal junction (GEJ) adenocarcinoma who responds to neoadjuvant chemoradiation therapy but declines surgery and develops progressive disease (HER2 1+, PD-L1 2%) — Minesh Dinubhai Patel, MD (13:54) Case: A frail woman in her late 80s with unresectable gastric cancer who chooses to receive systemic therapy (PD-L1 0%, HER2 negative, MSS) — Matthew R Strickland, MD (18:20) Case: A man in his mid 60s with T3N1M mixed gastric adenocarcinoma who responds well to neoadjuvant FLOT and has minimal residual disease at surgery — Ranju Gupta, MD (23:01) Case: A man in his early 60s with a history of prostate cancer who is now diagnosed with T2N1M0, HER2-positive GEJ adenocarcinoma — Dr Strickland (29:23) Case: A man in his early 30s with metastatic HER2-positive gastric adenocarcinoma who is responding well to FOLFOX, trastuzumab and nivolumab — Priya Rudolph, MD, PhD (33:00) Case: A man in his early 60s with metastatic HER2-positive esophageal cancer and a germline CHEK2 mutation who experiences disease progression on chemotherapy, pembrolizumab, trastuzumab and later T-DXd (PD-L1 12%) — Warren S Brenner, MD (46:34) Case: A man in his mid 70s with symptomatic anemia who is diagnosed with metastatic esophageal adenocarcinoma (PD-L1 8%, MSS, HER2 1+) — Dr Strickland (55:44) Case: A woman in her early 60s with squamous cell esophageal carcinoma metastatic to bone (PD-L1 TPS 10%) — Dr Strickland (58:46) CME information and select publications

Featuring a slide presentation and related discussion from Dr Asim Farooq, including the following topics: Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00) Immunotherapy for mismatch repair-proficient endometrial cancer (9:18) Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11) CME information and select publications

Featuring an interview with Dr Asim Farooq, including the following topics: Educating patients about ocular toxicities associated with anticancer therapies (0:00) Differentiating therapy-related ocular toxicities from symptoms not associated with anticancer drugs (3:44) Optimal prevention of ocular toxicities from antibody-drug conjugates; symptoms and management of central serous retinopathy (9:36) Pathophysiology of ocular symptoms associated with ALK inhibitors and BRAF/MEK inhibitors (16:40) Myths and misperceptions among physicians about ophthalmic toxicities (22:29) CME information and select publications

Featuring perspectives from Dr Stephen Liu, including the following topics: Introduction: Journal Club with Stephen V Liu, MD (0:00) Case: A woman in her mid 40s with metastatic lung adenocarcinoma with a ROS1 fusion — Minesh Dinubhai Patel, MD (10:54) Case: A woman in her late 70s with metastatic lung adenocarcinoma with a HER2 mutation — Adam R Miller, MD (17:40) Case: A woman in her early 60s with RET-fusion-driven lung adenocarcinoma — Kapisthalam (KS) Kumar, MD (22:30) Case: A woman in her early 70s with metastatic adenocarcinoma of the lung with a MET exon 14 mutation — Dr Kumar (31:02) Case: A woman in her early 70s with recurrent lung adenocarcinoma with a MET T263M mutation — Priya Rudolph, MD, PhD (34:15) Case: A woman in her late 70s with metastatic adenocarcinoma with a MET exon 14 mutation — Gigi Chen, MD (39:53) Case: A woman in her late 70s with ALK fusion-driven lung adenocarcinoma — Rajni Sinha, MD, MRCP (45:52) Case: A woman in her late 60s with metastatic lung adenocarcinoma and a KRAS G12C mutation — Dr Miller (52:08) Case: A woman in her early 60s with metastatic lung adenocarcinoma and an NRG1 fusion — Jiaxin (Jason) Niu, MD, PhD (57:06) CME information and select publications

Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics: Part 1: Case Presentations and Clinical Decision-Making (0:00) Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46) Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57) Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16) Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54) CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09) Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48) CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23) Bispecifics for multiple myeloma — Dr Chari (1:26:14) CME information and select publications

Featuring perspectives from Prof Jonathan Ledermann, including the following topics: Introduction (0:00) Case: An Asian woman in her early 80s with ovarian cancer and a gBRCA mutation receiving maintenance olaparib after surgery and adjuvant chemotherapy — Rao Mushtaq, MD (2:05) Journal Club with Prof Ledermann (7:58) Case: A woman in her mid 80s with gBRCA wild-type high-grade serous ovarian cancer (HGSOC) who develops recurrent disease after declining maintenance niraparib — Priya Rudolph, MD, PhD (17:28) Antibody-Drug Conjugates for Ovarian Cancer (23:09) Case: A woman in her mid 70s with HGSOC and gBRCA1 and 2 mutations who responds to olaparib for 5 years but then develops progressive disease after stopping — Karim ElSahwi, MD (33:38) Case: A woman in her late 60s with gBRCA wild-type Stage IIIC ovarian cancer who receives IV/IP adjuvant chemotherapy — Gigi Chen, MD (43:19) Case: A woman in her mid 40s with microsatellite instability-high BRCA wild-type clear cell ovarian cancer with stable disease on pembrolizumab — Syed F Zafar, MD (47:59) Case: A woman in her late 50s with recurrent BRCA wild-type (HRp) low-grade ovarian cancer with rising CA-125, pleural effusion and a new lung nodule on salvage chemotherapy — Dana M Chase, MD (52:48) Case: A woman in her early 90s with past medical history of untreated chronic lymphocytic leukemia who presents with Stage III/IV ovarian cancer — Rajalaxmi McKenna, MD (56:45) CME information and select publications